| Literature DB >> 30836275 |
Patricia Regina Manzine1, Miren Ettcheto2, Amanda Cano3, Oriol Busquets2, Elena Marcello4, Silvia Pelucchi5, Monica Di Luca4, Kristina Endres6, Jordi Olloquequi7, Antoni Camins8, Márcia Regina Cominetti9.
Abstract
Alzheimer's disease (AD) represents a global burden in the economics of healthcare systems. Amyloid-β (Aβ) peptides are formed by amyloid-β precursor protein (AβPP) cleavage, which can be processed by two pathways. The cleavage by the α-secretase A Disintegrin And Metalloprotease 10 (ADAM10) releases the soluble portion (sAβPPα) and prevents senile plaques. This pathway remains largely unknown and ignored, mainly regarding pharmacological approaches that may act via different signaling cascades and thus stimulate non-amyloidogenic cleavage through ADAM10. This review emphasizes the effects of natural compounds on ADAM10 modulation, which eventuates in a neuroprotective mechanism. Moreover, ADAM10 as an AD biomarker is revised. New treatments and preventive interventions targeting ADAM10 regulation for AD are necessary, considering the wide variety of ADAM10 substrates.Entities:
Keywords: ADAM10; Alzheimer’s disease; Natural compounds; Pharmaceutical; α-Secretase
Mesh：
Substances：
Year: 2019 PMID： 30836275 DOI： 10.1016/j.biopha.2019.108661
Source DB: PubMed Journal: Biomed Pharmacother ISSN： 0753-3322 Impact factor: 6.529